New Genetic Cause of Liver Fat Uncovered
Lead author Dr Mayada Metwally. Credit: The Westmead Institute for Medical Research
NAFLD is a major health concern in Western countries, with one in four people, including children, affected.
The international collaboration led by Associate Professor Mohammed Eslam and Professor Jacob George of the Westmead Institute for Medical Research, studied more than 1,000 patients with NAFLD to establish a link between genes and a build-up of fat in the liver, known as hepatic steatosis.
The team found that three genetic variations – FNDC5 rs3480, PNPLA3 1148M, and TM6SF2 E167K – were linked to increased fat in the liver.
Lead author Dr Mayada Metwally said the findings strengthened the link between genetics and liver disease, which could lead to new treatment options.
“Hepatic steatosis is one of the major risk factors for NAFLD, so if we can understand its causes, we can work towards preventing it,” she explained.
“We’ve previously thought that genes such as FNDC5, which help make a protein called irisin, play a role in depositing fat in the liver, but this is the first time we’ve demonstrated the link and identified the mechanisms.
“Our findings show that these genetic variants contribute to liver fat in people with NAFLD. The more variants a person has, the more likely they are to accumulate fat in the liver.”
Left untreated, NAFLD can also cause complications in the heart and kidneys.
“The growing number of people with NAFLD is alarming, particularly since many patients don’t develop symptoms until the condition is advanced,” Dr Metwally said.
“Understanding the genetic causes of NAFLD is crucial. We can now look towards targeting these genetic variations as a potential treatment to slow the progression of disease.”
This article has been republished from materials provided by The Westmead Institute. Note: material may have been edited for length and content. For further information, please contact the cited source.
A polymorphism in the Irisin-encoding gene (FNDC5) associates with hepatic steatosis by differential miRNA binding to the 3’UTR. Metwally, Mayada et al. Journal of Hepatology. DOI: https://doi.org/10.1016/j.jhep.2018.10.021
As genome editing technologies advance toward clinical therapies, they are raising hopes of a completely new way to treat disease. However, challenges need to be addressed before potential treatments can be widely used in patients. To tackle these challenges, the National Institutes of Health has launched the Somatic Cell Genome Editing program, which has awarded multiple grants including more than $3.6 million to assess the safety of genome editing in human cells and tissues.